Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology



    GOTHENBURG, Sweden, June 11 /CNW/ - Cellectricon, a leading provider of
screening solutions for drug discovery, today announced a new collaborative
agreement with AstraZeneca. Under the agreement Cellectricon will provide
AstraZeneca with two of its new groundbreaking high throughput platform,
Dynaflow(R)HT, for ion channel screening.
    Cellectricon and AstraZeneca formed and announced a collaboration in May
2006 aiming to find a solution to major bottlenecks in ligand gated ion
channel screening. The results from this collaboration have successfully
demonstrated the unique performance of Cellectricon's cell-based microfluidic
screening platform. It has clearly demonstrated the opportunity to introduce
the fully automated Dynaflow(R)HT System with unmatched level of stability and
throughput while still delivering unique measurement data quality. The
Dynaflow(R)HT System will be launched and commercially available in 2009.
    "Collaborating with AstraZeneca has been most rewarding," says Jonas
Ohlsson, CEO at Cellectricon. "Driven by solving bottlenecks in drug
discovery, Cellectricon's strategy is to bring state-of-the-art products for
drug discovery and research to the market through world-class customer
collaborations."
    "This collaboration aims to accelerate our efforts in ion channel drug
discovery and has been very fruitful to date. We look forward to working with
the Dynaflow@HT Systems and see the impact of their throughput and cost
effectiveness," says Dr. Jan-Erik Nystrom, VP Local Discovery Research Area
CNS & Pain Control, Sodertalje, Sweden.
    "The strength of this platform is that it is based on many years of
cutting-edge academic and industrial research in ion channel drug discovery. I
am happy to see us taking a new step together with a leading partner in
advancing it further," says Dr. Jon Sinclair, VP Research & Development at
Cellectricon.

    About Cellectricon

    Cellectricon AB (http://www.cellectricon.com), a Swedish biotech company,
successfully provides groundbreaking products to the pharmaceutical and
biotechnology industries. The company utilizes state-of-the-art interfaces to
biological systems by employing novel microfluidic technologies. This enables
completely new types of assays and devices with superior performance
characteristics and robustness. Cellectricon's products address critical
bottlenecks in the drug discovery process and have been adopted by
top-reference customers, including nine of the top ten pharmaceutical
companies. In 2007 the company increased its annual revenue by almost 50%. In
2008-2009 the company will launch two pioneering large-scale screening
platforms developed in close collaboration with leaders in the pharmaceutical
industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT
System enables high throughput RNAi screening and the Dynaflow(R)HT System
greatly advances ion channel drug discovery.




For further information:

For further information: Jonas Ohlsson, CEO, Phone : +46(0)709-73-47-92,
E-mail: jonas.ohlsson@cellectricon.com; Susanne Fagerlund, VP Market
Communications, Phone: +46(0)31-760-35-15, E-mail:
susanne.fagerlund@cellectricon.com

Organization Profile

CELLECTRICON AB

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890